# Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

> **NCT04047953** · NA · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 95 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1

## Key facts

- **NCT ID:** NCT04047953
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-10
- **Primary completion:** 2023-12-31
- **Final completion:** 2026-11
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047953, "Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04047953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*